Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 278.91 USD -4.18%
Market Cap: 149.8B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one AMGN stock under the Base Case scenario is 255.72 USD. Compared to the current market price of 278.91 USD, Amgen Inc is Overvalued by 8%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AMGN Relative Value
Base Case
255.72 USD
Overvaluation 8%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.5
P/S
P/S
Price to Sales
4.5
vs History
53
vs Industry
61
Median 3Y
4.9
Median 5Y
4.8
Industry
6.7
Forward
4.1
More Details
36.5
P/E
P/E
Price to Earnings
36.5
vs History
15
vs Industry
4
Median 3Y
20.8
Median 5Y
18.8
Industry
22.3
Forward
13.1
More Details
13
P/OCF
P/OCF
Price to OCF
13
vs History
28
vs Industry
11
Median 3Y
13.5
Median 5Y
12.7
Industry
19.4
More Details
45.7
P/FCFE
P/FCFE
Price to FCFE
45.7
vs History
3
vs Industry
4
Median 3Y
9.3
Median 5Y
10.3
Industry
23.8
More Details
25.5
P/B
P/B
Price to Book Value
25.5
vs History
33
vs Industry
2
Median 3Y
28
Median 5Y
20.2
Industry
2.3
More Details
5.8
EV/S
EV/S
Enterprise Value to Sales
5.8
vs History
36
vs Industry
45
Median 3Y
6.1
Median 5Y
5.8
Industry
7.3
Forward
5.4
More Details
9.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
9.4
vs History
22
vs Industry
39
Median 3Y
8.2
Median 5Y
7.6
Industry
9.1
More Details
15
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
15
vs History
22
vs Industry
9
Median 3Y
13
Median 5Y
11.8
Industry
3.8
Forward
9.2
More Details
26.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
26.6
vs History
17
vs Industry
5
Median 3Y
18.2
Median 5Y
16.1
Industry
3.6
Forward
12.1
More Details
16.9
EV/OCF
EV/OCF
Enterprise Value to OCF
16.9
vs History
23
vs Industry
10
Median 3Y
16.6
Median 5Y
15.4
Industry
4.4
More Details
18.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
18.6
vs History
25
vs Industry
7
Median 3Y
18.4
Median 5Y
17.1
Industry
2.9
More Details
3.3
EV/IC
EV/IC
Enterprise Value to IC
3.3
vs History
6
vs Industry
36
Median 3Y
2.9
Median 5Y
2.8
Industry
4.3
More Details

Multiples Across Competitors

AMGN Competitors Multiples
Amgen Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Amgen Inc
NASDAQ:AMGN
148.4B USD 4.5 36.5 15 26.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 210 447 -172 102.9 -208 987.7 -206 602.9
US
Abbvie Inc
NYSE:ABBV
300B USD 5.4 71.1 14.3 21.5
US
Gilead Sciences Inc
NASDAQ:GILD
125.3B USD 4.4 264.1 10.3 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD 11 -225.8 24.5 25.6
US
Epizyme Inc
F:EPE
94.1B EUR 1 945.5 -496.5 -540.6 -526.2
AU
CSL Ltd
ASX:CSL
117.1B AUD 4.7 26.1 16.2 20.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.5B USD 4.2 13.5 8 9
US
Seagen Inc
F:SGT
39.3B EUR 18.7 -57.5 -61.8 -55.8
NL
argenx SE
XBRU:ARGX
29.2B EUR 14.6 38.4 280.1 -2 063.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
29.7B USD 12.8 -103.2 -228.8 -155.5
P/S Multiple
Revenue Growth P/S to Growth
US
Amgen Inc
NASDAQ:AMGN
Average P/S: 3 292 043
4.5
4%
1.1
FR
Pharnext SCA
OTC:PNEXF
36 210 447
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.4
8%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
4.4
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11
10%
1.1
US
E
Epizyme Inc
F:EPE
1 945.5
N/A N/A
AU
CSL Ltd
ASX:CSL
4.7
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
7%
0.6
US
S
Seagen Inc
F:SGT
18.7
30%
0.6
NL
argenx SE
XBRU:ARGX
14.6
37%
0.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
12.8
28%
0.5
P/E Multiple
Earnings Growth PEG
US
Amgen Inc
NASDAQ:AMGN
Average P/E: 75
36.5
44%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -172 102.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
71.1
87%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
264.1
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -225.8 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -496.5 N/A N/A
AU
CSL Ltd
ASX:CSL
26.1
16%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
12%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.5 N/A N/A
NL
argenx SE
XBRU:ARGX
38.4
26%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -103.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Amgen Inc
NASDAQ:AMGN
Average EV/EBITDA: 52.6
15
17%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 987.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.3
13%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -540.6 N/A N/A
AU
CSL Ltd
ASX:CSL
16.2
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
NL
argenx SE
XBRU:ARGX
280.1
166%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -228.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Amgen Inc
NASDAQ:AMGN
Average EV/EBIT: 19.3
26.6
31%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -206 602.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.5
28%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.6
15%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526.2 N/A N/A
AU
CSL Ltd
ASX:CSL
20.3
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9
17%
0.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 063.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -155.5 N/A N/A

See Also

Summary
AMGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
AMGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AMGN stock valuation using valuation multiples.
Wall Street Estimates
AMGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AMGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 245,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.